



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** ☒ HIV-1 IIIB Virus

**Catalog Number:** 398

**Lot Number:** 070489

**Release Category:** C

**Provided:** 1 vial cell-free virus (TCID<sub>50</sub>=10<sup>6</sup>/ml titered in PBMCs, HIV p24=958ng/ml).

**Original Source:** Human patient peripheral blood or bone marrow from patients with AIDS or related diseases. Concentrated culture fluids of peripheral blood or bone marrow from several patients with AIDS or related diseases were used to establish a permanent productive infection in a cloned permissive neo-plastic T cell line (H9).

**Host Strain:** H9 cells. Also infects other human neo-plastic CD4<sup>+</sup> T cells including CEM, U937, Molt 3, HeLa CD4<sup>+</sup> cells, and human peripheral blood lymphocytes.

**Propagation:** Maintain cells in RPMI 1640 with L-glutamine, 80%; fetal bovine serum, 20% at 0.5-1 x 10<sup>6</sup> cells/mL for optimal growth. Split 1:2 or 1:4 every 2-3 days.

**Sterility:** Negative for bacteria, mycoplasma, and fungi.

**Description:** X4 (SI).

**Special Characteristics:** High capacity to replicate in human T cell lines. This virus appears to be well adapted for *in vitro* culture in T cells and replicates less well in fresh human macrophages. It utilizes CXCR4 as a co-receptor. Host: H9. Also infects other human neo-plastic CD4<sup>+</sup> T cells including CEM, U937, Molt 3, HeLa CD4<sup>+</sup> cells, and human peripheral blood lymphocytes. Preparation: Maintain cells in RPMI 1640 with L-glutamine, 80%; fetal bovine serum, 20% at 0.5-1 x 10<sup>6</sup> cells/ml for optimum growth. Split 1:2-1:4 every 2-3 days.

**Alternative Name: HTLV-III B/H9**

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Recommended Storage:** Liquid nitrogen.

**Contributor:** Dr. Robert Gallo.

**References:** Popovic M, Read-Connole E, Gallo RC. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. *Lancet* **ii**:1472-1473, 1984. Popovic M, Sarngadharan MG, Read E, Gallo, RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science* **224**:497-500, 1984. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR Jr, Pearson ML, Lautenberger JA, Papas TS, Ghrayab J, Chang NT, Gallo RC, Wong-Staal F. Complete nucleotide sequence of the AIDS virus, HTLV-III. *Nature* **313**:277-283, 1985.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 IIIB Virus from Dr. Robert Gallo." Also include the references cited above in any publications. .

**Scientist at for-profit institutions or who intend commercial use of this reagent must contact Dr. Susan Ano, Office of Technology Transfer, National Institute of Health, 6011 Executive Blvd, Suite 325, Rockville, MD 20852, Tel:(301) 435-5515, Fax:(301) 402-0220, Email: [anos@mail.nih.gov](mailto:anos@mail.nih.gov), Website: <http://ott.od.nih.gov>, before the reagent can be released.**

**Last Updated:** June 19, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.